Magazine Article | July 1, 2021

Preferred Provider Type By Clinical Research Phase

Source: Life Science Leader

By Industry Standard Research

In a recent survey focused on clinical development outsourcing, respondents were asked which provider type they would choose if the choice were completely up to them. The longest bar in the adjacent chart stands out — large CROs are overwhelmingly preferred by respondents for conducting Phase 3 trials. Large CROs are also preferred for conducting Phase 4 trials (65% — an uptick of 20 ppts since 2018). Midsized CROs are preferred by respondents for Phase 2 trials (59%). Phase 1 provider preference is fairly mixed.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader